# reload+after+2024-01-23 12:46:06.477803
address1§5 Radnor Corporate Center
address2§Suite 500 100 Matsonford Road
city§Radnor
state§PA
zip§19087
country§United States
phone§484 801 4670
website§https://marinuspharma.com
industry§Biotechnology
sector§Healthcare
longBusinessSummary§Marinus Pharmaceuticals, Inc., a pharmaceutical company, focuses on development and commercialization of therapeutic products for patients suffering from rare genetic epilepsies and other seizure disorders. It offers ZTALMY (ganaxolone), an oral suspension for the treatment of seizures associated with cyclin-dependent kinase-like 5 deficiency disorder for adult and pediatric patient populations in acute and chronic care, and in-patient and self-administered settings. The company's ZTALMY product candidate acts at synaptic and extrasynaptic GABAA receptors, a target for its anti-seizure, antidepressant, and anxiolytic potential. It is developing ganaxolone for treating genetic epilepsy disorders, such as PCDH19-related epilepsy, and tuberous sclerosis complex. Marinus Pharmaceuticals, Inc. has license agreement with Purdue Neuroscience Company and CyDex Pharmaceuticals, Inc.; and collaboration agreement with Orion Corporation and Tenacia Biotechnology (Shanghai) Co., Ltd. The company was incorporated in 2003 and is headquartered in Radnor, Pennsylvania.
fullTimeEmployees§151
companyOfficers§[{'maxAge': 1, 'name': 'Dr. Scott N. Braunstein M.D.', 'age': 60, 'title': 'CEO, President & Chairman', 'yearBorn': 1963, 'fiscalYear': 2022, 'totalPay': 919290, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Mr. Steven E. Pfanstiel C.M.A., M.B.A.', 'age': 49, 'title': 'COO, CFO & Treasurer', 'yearBorn': 1974, 'fiscalYear': 2022, 'totalPay': 580350, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Dr. Joseph  Hulihan M.D.', 'age': 67, 'title': 'Chief Medical Officer', 'yearBorn': 1956, 'fiscalYear': 2022, 'totalPay': 639510, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Dr. Alex  Aimetti Ph.D.', 'title': 'Chief Scientific Officer', 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Ms. Sonya  Weigle', 'title': 'Senior VP of Investor Relations, Human Resources & Corporate Affairs', 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Ms. Martha E. Manning Esq., J. D.', 'age': 68, 'title': 'Senior VP, General Counsel & Secretary', 'yearBorn': 1955, 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Molly  Cameron', 'title': 'Director of Corporate Communications & Investor Relations', 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Dr. Kimberly A. McCormick Pharm.D.', 'title': 'Chief Regulatory & Quality Assurance Officer', 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Mr. Thomas J. Lyons', 'title': 'Chief Business Officer', 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Ms. Christina  Shafer', 'age': 47, 'title': 'Chief Commercial Officer', 'yearBorn': 1976, 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}]
auditRisk§2
boardRisk§8
compensationRisk§10
shareHolderRightsRisk§6
overallRisk§9
governanceEpochDate§1704067200
compensationAsOfEpochDate§1672444800
maxAge§86400
priceHint§2
payoutRatio§0.0
beta§0.977
priceToSalesTrailing12Months§19.107195
currency§USD
dateShortInterest§1702598400
forwardEps§-2.26
pegRatio§-0.21
exchange§NGM
quoteType§EQUITY
shortName§Marinus Pharmaceuticals, Inc.
longName§Marinus Pharmaceuticals, Inc.
firstTradeDateEpochUtc§1406813400
timeZoneFullName§America/New_York
timeZoneShortName§EST
uuid§fa2311e7-a277-341e-95c3-c3f56aa168dd
gmtOffSetMilliseconds§-18000000
targetHighPrice§28.0
targetLowPrice§9.0
targetMeanPrice§20.3
targetMedianPrice§21.0
recommendationMean§1.7
recommendationKey§buy
numberOfAnalystOpinions§10
quickRatio§5.912
grossMargins§-2.09321
ebitdaMargins§0.0
trailingPegRatio§None
